176 related articles for article (PubMed ID: 33667323)
1. Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Yagi K; Ishida Y; Otsuka A; Kabashima K
Australas J Dermatol; 2021 Aug; 62(3):433-434. PubMed ID: 33667323
[No Abstract] [Full Text] [Related]
2. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
3. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K
J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380
[No Abstract] [Full Text] [Related]
4. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Noji S; Hara Y; Miura T; Yamanaka H; Maeda K; Hori A; Yamamoto H; Obika S; Inoue M; Hase Y; Orita T; Doi S; Adachi T; Tanimoto A; Oki C; Kimoto Y; Ogawa Y; Negoro T; Hashimoto H; Shiozaki M
J Med Chem; 2020 Jul; 63(13):7163-7185. PubMed ID: 32511913
[TBL] [Abstract][Full Text] [Related]
8. Delgocitinib: First Approval.
Dhillon S
Drugs; 2020 Apr; 80(6):609-615. PubMed ID: 32166597
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
11. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
13. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Hayashi M; Okamura K; Abe Y; Hozumi Y; Suzuki T
J Dermatol; 2019 Jun; 46(6):548-550. PubMed ID: 30969438
[No Abstract] [Full Text] [Related]
15. New Indication for Topical Ruxolitnib.
Aschenbrenner DS
Am J Nurs; 2022 Nov; 122(11):21. PubMed ID: 36261902
[TBL] [Abstract][Full Text] [Related]
16. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T; Kołkowski K; Nowicki RJ; Sokołowska-Wojdyło M
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298700
[TBL] [Abstract][Full Text] [Related]
17. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
19. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.
Joshipura D; Alomran A; Zancanaro P; Rosmarin D
J Am Acad Dermatol; 2018 Jun; 78(6):1205-1207.e1. PubMed ID: 29438765
[No Abstract] [Full Text] [Related]
20. Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells.
Azzolino V; Zapata L; Garg M; Gjoni M; Riding RL; Strassner JP; Richmond JM; Harris JE
J Invest Dermatol; 2021 Jan; 141(1):182-184.e1. PubMed ID: 32464150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
